Retail Offer to raise up to £100,000

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") of nil par value each in the Company (the "Retail Offer Shares") at an issue price of 10.0 pence per New Ordinary Share (as defined below) (the "Issue Price") to raise up to £100,000.

In addition to the Retail Offer, the Company is also conducting a placing of new ordinary shares (the "Placing Shares" and together with the Retail Offer Shares, the "New Ordinary Shares") at the Issue Price (the "Placing" and together with the Retail Offer, the "Issue"). A separate announcement has been made regarding the Placing and its terms. For the avoidance of doubt, the Retail Offer is not part of the Placing.

The Retail Offer is conditional on the approval of shareholders at a general meeting of the Company expected to be held on 15 June 2026 (the "General Meeting"), and the New Ordinary Shares to be issued pursuant to the Retail Offer being admitted to trading on the AIM market operated by the London Stock Exchange ("Admission"). Admission of the New Ordinary Shares pursuant to the Retail Offer is expected to take place on 16 June 2026. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.

The net proceeds of the Issue will:

o Provide the Company with the finance required to help secure significant grant funding, subject to confirmation;

o Progress the Phase 2 open-label clinical trial of irinotecan-ChemoSeed for the treatment of glioblastoma;

o Support the continued development of docetaxel-ChemoSeed for prostate cancer; and

o Provide the Company with additional working capital.

Expected Timetable in relation to the Retail Offer

Retail Offer

The Company values its retail shareholder base. Given the support of retail shareholders, the Company believes that it is appropriate to provide its retail shareholders in the United Kingdom the opportunity to participate in the Retail Offer. The Company is therefore making the Retail Offer available in the United Kingdom through the financial intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/21E8Y7/authorised-intermediaries

SP Angel Corporate Finance LLP will be acting as retail offer coordinator in relation to this Retail Offer (the "Retail Offer Coordinator").

The Retail Offer will be open to eligible investors in the United Kingdom at 7:30am on 26 May 2026. The Retail Offer is expected to close at 11:00am on 28 May 2026. Investors should note that financial intermediaries may have earlier closing times. The Retail Offer may close early if it is oversubscribed. The Company also reserves the right to increase the Retail Offer at its discretion, should the Retail Offer become oversubscribed.

It is a term of the Retail Offer that the total aggregate consideration payable for the Retail Offer Shares will not exceed £100,000.The Retail Offer is offered in the United Kingdom under an exemption from the prohibition of public offers specified in Part 1 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024.

There is a minimum subscription of £100.00 per investor under the terms of the Retail Offer which is open to investors in the United Kingdom subscribing via the intermediaries which will be listed, subject to certain access restrictions, on the following website: https://www.bookbuild.live/deals/21E8Y7/authorised-intermediaries

UK Product Governance Requirements

EU Product Governance Requirements

The Company's LEI is 213800XFW6MKVCHHPW88.